Conclusion
The COVID-19 can cause a variety of neurological manifestations and physicians have to be vary of them when they come across affected patients in this pandemic. There are no disease defining imaging findings on MRI brain and the yield of PCR analysis of CSF is low so basically it is a diagnosis of exclusion and we have to rule out the more common causes of encephalitis first to reach this diagnosis like we did in our study. There is not enough data present to definitely conclude whether there will be any permanent neurological damage or not, our study points us in the direction that complete recovery without any long lasting neurological damage is possible in such patients. To determine the exact efficacy and effectiveness of the current proposed treatment for COVID-19 encephalitis will require clinical trials but the result of our study show promising results of IV Tocilizumab (4-8 mg/kg) and IV methylprednisolone (0.5-2 mg/kg).
The purpose of our study is to highlight the importance of neurological manifestations of COVID-19 and to point to the fact that such a diagnosis has to be considered when a patient presents with such signs and symptoms. Our case series will add to the much deficient knowledge on the subject of neurological manifestations of COVID-19.